Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Chinese clinical oncology
- Publicado em
- 28 abr 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis
Bannawich Sapapsap, Sirapratch Champarhorm, Anchana Pongpun, Nattapong Kanchana, Jittipon Tantivit, Nattawut Leelakanok
Descritores MeSH
- Colorectal Neoplasms
- Pyrrolidines
- Trifluridine
- Uracil
- Antineoplastic Combined Chemotherapy Protocols
- Phenylurea Compounds
- Pyridines
- Drug Combinations
- Humans
- Neoplasm Metastasis
Veja também
Estudos relacionados
- A systematic review of cost-effectiveness studies of later-line treatments for refractory metastatic colorectal cancer
- Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
- Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
- Survival benefit of oral systemic monotherapy in previously treated metastatic colorectal cancer: a meta-analysis